How common is treatment inertia in the treatment of adult patients with T2D and what can be done about it? Join a multidisciplinary panel including Jim Gavin, MD, PhD; Steve Vacalis, DO; and Jodi Strong, DNP, CDE, BC-ADM, CPT as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.

This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.

US22RYB00922_Rybelsus Pioneer 3 Enduring Video.mp4